CGM

HbA1c values also declined across a sample of program participants, many of whom said they were unfamiliar with the diabetes management tools prior to enrollment.

Dexcom CEO Kevin Sayer has seen the company through some boom years, including growth that has outpaced the company's manufacturing capabilities. But they've learned lessons and are pressing on with a new, smaller sensor in 2021.

Dexcom G6 users will now be able to integrate their continuous glucose monitor to the Livongo platform for more personalized insights and coaching. 

While Dexcom reports that interruptions in the service are mostly under control, many customers are critiquing the company's poor messaging of the issue, which they say could be fatal.

This is the seventh FDA clearance for the longstanding mobile diabetes management platform.

Senseonics initiated the recall voluntarily in September after receiving reports of 24 sensors that had stopped functioning prematurely. 

The technology includes one-time use sensors and can switch between blind and unblinded mode. 

These management devices are "no longer a minor presence relative to the various drug therapies," CEO Kevin Sayer said during the call.

The company's executives lauded the CGM system, which saw a 72.9% increase in organic sales during the last quarter, and hinted at implementations of the tech beyond diabetes alone.

The FDA approval closes a gap with competitors Dexcom and Abbott, as well as setting the company up for entry into the Medicare market.